PROxy Network, an initiative of PeriPharm inc.
Montreal, Quebec, H2Y 2H4, Canada
NCT Number: NCT06610045
The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL. Additionally, this study will assess the correlation between QoL, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Montreal, Quebec, H2Y 2H4, Canada
Potential participants will be identified by Myeloma Canada using their database. Myeloma Canada is a registered non-profit organization created by, and for, Canadians impacted by multiple myeloma. As part of Myeloma Canada website, patients and caregivers can subscribe to a mailing list to receive their monthly newsletter and to participate in surveys. This database comprises about 5,000 individuals, including patients and caregivers.
An e-mail will be sent to 600 patients and 200 caregivers randomly selected to invited them to participate in the survey. Interested participants will be invited to visit the Participant Portal on the PROxy website (https://periproxy.com/en), to sign the informed consent form and complete online questionnaires. Upon request, paper-based documents (i.e., informed consent form and questionnaires) can also be sent by mail. The following questionnaires will be used:
Patients
Caregivers
If the sample size (i.e., 300 patients and 100 caregivers) is not reached one month after the first e-mail, an invitation e-mail will be sent to an additional 600 eligible patients and/or 200 caregivers randomly selected. This scheme of participant identification will be performed until the sample size is reached.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No exclusion criteria
No specific intervention is assess in this study.
Time frame: From enrollment until sample size is reached
Time frame: From recruitment until sample size is reached
PeriPharm
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01242930
Blood Protein Disorders, Cardiovascular Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT05831787
Blood Protein Disorders, COVID-19
New York, United States
View Trial DetailsNCT04354246
Adnexal Diseases, Advanced Cancer
Sarasota, Florida, United States
View Trial DetailsNCT00339963
Blood Protein Disorders, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial Details